JPMorgan Chase & Co. (NYSE:JPM) Stake Raised by Arcus Capital Partners LLC
Arcus Capital Partners LLC grew its holdings in shares of JPMorgan Chase & Co. (NYSE:JPM) by 31.7% during the fourth quarter, ...
Arcus Capital Partners LLC Has $1.56 Million Holdings in Meta Platforms, Inc. (NASDAQ:META)
Arcus Capital Partners LLC boosted its position in Meta Platforms, Inc. (NASDAQ:META – Free Report) by 6.9% during the fourth ...
BioSpace4d
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
2RCUS : Arcus Biosciences Shares Are Down Today: What's Going On?
Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...
The American Journal of Managed Care5d
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...
The Pharma Letter5d
Gilead looks on as Arcus casdatifan data hints at potential
California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...
BioSpace5d
Arcus Challenges Merck in Kidney Cancer with Early Data
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...
Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The ...
PipelineReview.com5d
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
HAYWARD, CA, USA I 15, 2025 I Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing ...